Figure 1



Colon HCT-116 CSCs
PRP
IC50= >10
r2= 0.97
Pancreatic BxPC3 CSCs
PRP
IC50= 7.0
r2= 0.99
IFN+PRP
IC50= >10
r2= 0.98
IFN+PRP
IC50= 2.9
r2= 0.99
Rate of Cell Proliferation
Treatment Concentration

Figure 2



Pancreatic Non-CSCs
Pancreatic CSCs
G1
G0/G1
S
G2/M
% Cells
CTL
IFN
PRP
PRP+IFN
PRP+INF
a
b
c
d

Figure 3



Colon Non-CSCs
Colon CSCs
G1
G0/G1
S
G2/M
% Cells
CTL
IFN
PRP
PRP+IFN
a
b
c
d

Figure 4



Pancreatic Non-CSCs
25
20
15
10
5
0
CTL
PRP
PRP+IFN
INTF
Pancreatic CSCs
60
50
40
30
20
10
0
CTL
PRP
PRP+IFN
INTF

Figure 5

Pancreatic CSC, BXPC3
Triple labelling: CD326 CD44 CxCR4

A. 1st Assay




Figure 5 (continued)




Figure 5 (continued)




Figure 5 (continued)




Figure 5 (continued)

B. 2nd Assay




Figure 5 (continued)




Figure 5 (continued)





Figure 5 (continued)



Substitue Sheets
(Rule 26)
RO/AU

Figure 6



% Expression triple labelling: CD 326, CD 44, CxCR4
1st assay
45
40
35
30
25
20
15
10
5
0
Non-CSC
CTL CSC
CSC PRP
CSC PRP+IFN
CSC IFN
2nd assay
60
50
40
30
20
10
0
Non-CSC
CTL CSC
CSC PRP
CSC PRP+IFN
CSC IFN

Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Non-treated neuroblatoma CSC
PRP treated neuroblatoma CSC
A
B
C
D

Figure 11 continued

E



F



Substitue Sheets
(Rule 26)
RO/AU

Figure 12





Figure 13



Substitue Sheets
(Rule 26)
RO/AU

Figure 14




A.
CONTROL
PREVENTIVE
PREVENTIVE AND TREATED
TREATED
3 weeks
3-4 months
B.
CONTROL CSCs
IC50 PRP CSCs
2x IC50 PRP CSCs
5xIC50 PRP CSCs
3-6 days
3-4 months

Figure 14 continued

C.



Substitue Sheets
(Rule 26)
RO/AU

Figure 15




Figure 16






Figure 17



Substitue Sheets
(Rule 26)
RO/AU

Figure 18

A.


250
200
150
100
50
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
CONTROL
PREVENTIVE
PREVENTIVE+PRP

B.





PRP group Rate Based T/C= 0.54
PRP +PRP group Rated Base T/C= 0.13
Tumor volume (mm3)
700
600
500
400
300
200
100
0
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34
Days
*
*
CONTROL
PRP
PRP+PRP

Figure 19



Substitue Sheets
(Rule 26)
RO/AU

Figure 20



Substitue Sheets
(Rule 26)
RO/AU

Figure 21




Figure 22



A
Genes down-Regulated during EMT
Fold Regulation Comparing to Control
7
6
5
4
3
2
1
KLF17
E-Cadherin
MST1R
TFP12
NUDT13
OCL
B
Genes up-Regulated during EMT
1
0
-1
-2
-3
-4
-5
-6
SNAI1
SNAI2
COL3A1
FN1
TGFBR2
ITGA5
ITGAV
MMP2
MSN
SERPINE1
TIMP3
TMEM132A
VIM
NCAM1

Figure 23




Figure 24




Figure 25



A
Fold Regulation Comparing to Control
1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
PCALR
BMP7
DKK1
ITGB1
PLAT
FN1
ITGB4
PDGFRB
SPP1
B
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0
FZD7
DSC2
E-CAD
b-cat
DSP
PTK2
RAC1

Figure 26



CCR1
ICAM
PECAM1
MMP8
IL8
KRAS
1
2
3
4
5
6
7
Fold Regulation Comparing to Control

Figure 27




CD34
CD31
CD90
MYC
NANOG
PROM1
CD45
SOX2
CD44
CD133
CD105
25
20
15
10
5
0
-5
-10
-15
Fold Regulation Comparing to Control

Figure 28


MEK1
FOS
JUN
MAP3K1
MAP2K4
MAP2K6
p21
CDK1
1
0
1
2
3
4
5
6
7
8
9
Fold Regulation Comparing to Control